A team of Spanish researchers, led by biochemist Mariano Barbacid, is able to eliminate the most frequent pancreatic mice in the mice for the first time. It's about it deadly tumors let alone and of which only 5% of patients with this disease live fifty years. As Barbacid, this weekend at a press conference in Madrid, "I am very trying to give false hope. I want to make it clear that it does not work for people who currently have pancreatic cancer." Qualified: "This is what it takes to open new animals".
In most cases, the incipient mutation of pancreatic tumors appears in & # 39; e people in the CRAS, a gene under normal conditions the simultaneous operation of & # 39; e cell. Since its discovery in 1982, scientists published about 36,000 studies on the gene and its onset of cancer, but there is still no drug to neutralize their activities as they proliferate. "We are incompetent or half-complex," said Barbacid, of the National Cancer Research Center (CNIO), in Spain's capital.
The realization of this team is based on the genetic modification of 12 rodents, with the purpose of presenting the same mutations in KRAS and another community in another gene, TP53. Then the healing of the mouse is renamed to reach the neutralization of a molecule from & # 39; e mutation in & quot; KRAS gene (c-Raf) and blocking another from & # 39; a habit in cancer: the factor receptor epidermal growth. This severe genetic modification, probably in humans, has been able to change cancer and then neutralize in six of the treated mice.
The CNIO has stated in a statement that "until now the disappearance (complete repression) of whole pancreatic cancer has never been assessed in all experimental models." And as published in a magazine Cancer Cell, this experimental approach has also taken nine & # 39; to place and cultivate ten human pancreatic tumors in other immunosuppressed mice. Unfortunately, Barbacid warned that the implementation of this strategy would not occur for five or ten years, assuming it is coming.
Doctor Enrique de Madaria, vice-president of the Spanish Association of Pancreatology, said that "the study opens a research podium to improve the prognosis of patients with pancreatic cancer, but It is not very applicable in patients"And he adds," At present, no drugs are blocking selection of c-RAF without involuntary effects at other levels. "For his part, De Madaria, a specialist at the General University Hospital of Alicante , said "this study calls for research into new medicines that hope to pancake patients."
Marta Puyol, director of the Spanish Cancer Society, has requested & # 39; a political party press conference to accept as soon as possible a national cancer research strategy, with the aim of earning investment and 70% of total survival in Spain by the year 2030. Currently, 53% of patients are still fifty years after the diagnosis survives , a sufficient period is considered whole in many tumors. Success changed from 85% in breast cancer to 5% in pancreatic tumors.
The goal now is to "get what Mariano wants in patients [Barbacid] Come in your mouse, "said Carrato. The oncologist has described the cold dimension of the enemy. People with pancake seas have very non-specific symptoms, such as abuse, weight loss, and scab or ribbon blood." patient to suffer one year back and not to seek cancer until it gets paid, "Carrato said. "It's a reality you & # 39; t are for the diagnosis". And if the tumor is recognized, surgery can no longer be performed and chemotherapy and radiotherapy treatments are not effective.
That's why it's worthwhile to work out what potentially new treatments for this tumor deliver, "said Dr. Teresa Macarulla, University of California's Vall d 'Hebron, in Barcelona. This "hopeful" study, but "we need to be careful with the results, given that the authors reported data from a few models".